KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle implizite Wahrscheinlichkeit
Above 8% 92%Führend unter 9 Optionen
Marktqualitat
62 / 100
Mittlere Qualität24h-Volumen
2605,5 €
Liquidität
2261,8 €
Mittlere LiquiditätSpread
1.0 pt
Enger SpreadMarktdaten
Aktualisiert vor 4 Minuten
9. Sept. 26, 02:00 UTC31. März 27, 05:00 UTC
Trends
0%
0%
0%
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
Medtronic cardiovascular organic growth in fiscal 2027
KalshiWill I believe the post "Cardiovascular disease is a solved problem" is broadly correct in August 2028?
Manifold MarketsWhen will Compass Pathways submit a NDA for COMP360 psilocybin?
KalshiWill 3 mg THC beverages be federally legal to sell?
KalshiWill there be >250k tech layoffs in 2027 according to Layoffs.fyi?
Manifold MarketsWill Aurelia Song abandon Nectome before 2041?
Manifold MarketsRegeln
If Medtronic plc reports Above 8% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
Abwicklung über:Fiscal.ai
- Kalshi is not affiliated, associated, authorized, endorsed by, or in any way officially connected with the underlying company.
- All trademarks, logos, and brand names are the property of their respective owners.
- If Medtronic plc reports Above 9% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- If Medtronic plc reports Above 10% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- If Medtronic plc reports Above 10.5% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
Offene Märkte
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Gesamtvolumen
- 15,6 Mio. €
- 24h-Volumen
- 20.404 €
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Gesamtvolumen
- 918.998,9 €
- 24h-Volumen
- 4170,6 €
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k+0.1pt100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 weitere Ergebnisse
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000+3.0pt61%
+2 weitere Ergebnisse
- Gesamtvolumen
- 866.739 €
- 24h-Volumen
- 1697 €
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Gesamtvolumen
- 611.782,3 €
- 24h-Volumen
- 1101 €
KALSHIWhen will Beam Therapeutics submit a BLA for Risto-cel?
- before April 202793%
- before 202756%
- before December49%
+3 weitere Ergebnisse
- Gesamtvolumen
- 19.131,2 €
- 24h-Volumen
- 1018 €
- Which countries will report an Ebola disease case before October?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Heidi Overton confirmed as FDA Commissioner by which date?
- Will the FDA approve retatrutide?
- Ebola pandemic in 2026?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- Measles cases in U.S. by September 30?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- FDA approves Retatrutide this year?
- How many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
Häufige Fragen
- Wie stehen die aktuellen Quoten für Medtronic cardiovascular growth in Q2?
- Kalshi bewertet Above 8% mit 92% (Stand: 10. September 2026).
- Wann wird Medtronic cardiovascular growth in Q2 entschieden?
- Medtronic cardiovascular growth in Q2 soll am 31. März 2027 entschieden werden.
- Wie wird Medtronic cardiovascular growth in Q2 abgerechnet?
- Kalshi rechnet diesen Markt wie folgt ab: If Medtronic plc reports Above 8% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.